Challenges in treating patients with Major depressive disorder: The impact of biological and social factors

CNS Drugs

Volumn 27, Issue SUPPL.1, 2013, Pages

  Sato, Soichiro ^a   Yeh, Tzung Lieh ^b  

^a Zikei Hospital   (Japan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; CLINICAL FEATURE; COMORBIDITY; DIABETES MELLITUS; ECONOMIC ASPECT; HEART INFARCTION; HUMAN; MAJOR DEPRESSION; PHYSICAL ACTIVITY; PHYSICAL DISEASE; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; SOCIAL ASPECT; SOCIAL INTERACTION; PREVALENCE; PSYCHOLOGICAL ASPECT; SOCIAL BEHAVIOR; SOCIOECONOMICS;

COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; HUMANS; PREVALENCE; SOCIAL BEHAVIOR; SOCIOECONOMIC FACTORS;

EID: 84886279008     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0028-8     Document Type: Review

References (34)

1. Murray CJ, Lopez AD. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science. 1996;274: 740-3.
2. Murray CJ, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 projected to 2020. Cambridge: Harvard School of Public Health; 1996.
3. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-27.
4. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291:2581-90.
5. Ministry of Health, Welfare and Labour, Japan. National survey of injuries and diseases in Japan (in Japanese). http://www.e-stat.go.jp/SG1/estat/ NewList.do?tid=000001031167. Accessed Aug 2012.
6. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-105.
7. Kessler RC, Birnbaum H, Bromet E, Hwang I, Sampson N, Shahly V. Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). Psychol Med. 2010;40:225-37.
8. Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, et al. STAR&z.ast;D: revising conventional wisdom. CNS Drugs. 2009;23:627-47.
9. Association AP. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Publishing; 1994.
10. Nakao M, Yamanaka G, Kuboki T. Major depression and somatic symptoms in a mind/body medicine clinic. Psychopathology. 2001;34:230-5.
11. Zhu C, Ou L, Geng Q, Zhang M, Ye R, Chen J, et al. Association of somatic symptoms with depression and anxiety in clinical patients of general hospitals in Guangzhou, China. Gen Hosp Psychiatry. 2012;34:113-20.
12. Kellner R, Sheffield BF. The one-week prevalence of symptoms in neurotic patients and normals. Am J Psychiatry. 1973;130: 102-5.
13. Kroenke K, Spitzer RL, Williams JB, Linzer M, Hahn SR, de-Gruy FV, III, et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med. 1994;3:774-9.
14. Kroenke K, Bair MJ, Damush TM, Wu J, Hoke S, Sutherland J, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA. 2009;301: 2099-110.
15. Kroenke K, Bair M, Damush T, Hoke S, Nicholas G, Kempf C, et al. Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP) study: design and practical implications of an intervention for comorbid pain and depression. Gen Hosp Psychiatry. 2007;29:506-17.
16. Tylee A, Gastpar M, Lepine JP, Mendlewicz J. Identification of depressed patient types in the community and their treatment needs: findings from the DEPRES II (Depression Research in European Society II) survey. DEPRES Steering Committee. Int Clin Psychopharmacol. 1999;14:153-65.
17. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171-80.
18. Pae CU, Marks DM, Shah M, Han C, Ham BJ, Patkar AA, et al. Milnacipran: beyond a role of antidepressant. Clinical neuropharmacology. 2009;32:355-63.
19. Pae CU, Marks DC, Han C, Patkar AA, Masand PS. Duloxetine: an emerging evidence for fibromyalgia. Biomed Pharmacother. 2009;63:69-71.
20. Perahia DG, Quail D, Desaiah D, Montejo AL, Schatzberg AF. Switching to duloxetine in selective serotonin reuptake inhibitor non-and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res. 2009;43:512-8.
21. Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med. 2004;19:813-8.
22. Yates WR, Mitchell J, Rush AJ, Trivedi MH, Wisniewski SR, Warden D, et al. Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR&z.ast;D. Gen Hosp Psychiatry. 2004;26:421-9.
23. Lesperance F, Frasure-Smith N, Talajic M, Bourassa MG. Fiveyear risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation. 2002;105:1049-53.
24. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31:2383-90.
25. Sutor B, Rummans TA, Jowsey SG, Krahn LE, Martin MJ, O'Connor MK, et al. Major depression in medically ill patients. Mayo Clin Proc. 1998;73:329-37.
26. Baumeister H, Hutter N. Collaborative care for depression in medically ill patients. Curr Opin Psychiatry. 2012;25:405-14.
27. Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 2011;13:7-23.
28. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851-8.
29. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262: 914-9.
30. Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 2006;163:1561-8.
31. University K. Report on the estimate of the social cost of mental disorders (in Japanese). http://www.mhlw.go.jp/bunya/shougaihoken/cyousajigyou/ dl/seikabutsu30-2.pdf. Accessed Aug 2012; 2011.
32. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 1998;59:608-19.
33. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry. 2000;157:1925-32.
34. Maixner SM, Greden JF. Extended antidepressant maintenance and discontinuation syndromes. Depress Anxiety. 1998;8(Suppl. 1): 43-53.